Home World News EMA Recommends Granting a Marketing Authorisation for Tarlatamab World News EMA Recommends Granting a Marketing Authorisation for Tarlatamab By Ogkologos - April 17, 2026 322 0 Facebook Twitter Google+ Pinterest WhatsApp It is indicated for the treatment of adult patients with extensive-stage SCLC Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Expanding the horizons of the life science economy May 3, 2022 Mom Who Lost Child Donates Breast Milk To Mom With Cancer February 27, 2019 Breast Cancer Patients with Low Breast Density May Be More Likely... January 18, 2021 EMA Recommends Granting a Conditional Marketing Authorisation for Loncastuximab Tesirine September 22, 2022 Load more HOT NEWS 4,000 Cancer Patients Affected by Diluted Chemotherapy Doses from Crooked Pharmacist Do as I say, not as I do – when the... FDA Approves Fruquintinib for Patients with Refractory Metastatic Colorectal Cancer Forging Military Partnerships to Empower the Cancer Research Enterprise
